49 related articles for article (PubMed ID: 9663363)
1. Cerivastatin: a cellular and molecular drug for the future?
Siegel-Axel DI
Cell Mol Life Sci; 2003 Jan; 60(1):144-64. PubMed ID: 12613664
[TBL] [Abstract][Full Text] [Related]
2. Should we lower cholesterol as much as possible? Cholesterol is good?
de Wolff JF
BMJ; 2006 Jun; 332(7555):1453. PubMed ID: 16777899
[No Abstract] [Full Text] [Related]
3. [Continuing medical education about the use of antilipemic agents in elderly patients aged 65-75 years].
Ruiz García A; Villares Rodríguez J; Herreros Tabernero B; Hermosa Hernán J; del Pozo Sosa G; Gordillo López F
Aten Primaria; 2001 Mar; 27(4):250-7. PubMed ID: 11262334
[TBL] [Abstract][Full Text] [Related]
4. Cerivastatin for lowering lipids.
Adams SP; Tiellet N; Alaeiilkhchi N; Wright JM
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012501. PubMed ID: 31981471
[TBL] [Abstract][Full Text] [Related]
5. Bile acid binding resin improves metabolic control through the induction of energy expenditure.
Watanabe M; Morimoto K; Houten SM; Kaneko-Iwasaki N; Sugizaki T; Horai Y; Mataki C; Sato H; Murahashi K; Arita E; Schoonjans K; Suzuki T; Itoh H; Auwerx J
PLoS One; 2012; 7(8):e38286. PubMed ID: 22952571
[TBL] [Abstract][Full Text] [Related]
6. Statin use and the risk of cholecystectomy in women.
Tsai CJ; Leitzmann MF; Willett WC; Giovannucci EL
Gastroenterology; 2009 May; 136(5):1593-600. PubMed ID: 19208351
[TBL] [Abstract][Full Text] [Related]
7. Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety.
Stein E
Am J Cardiol; 1998 Aug; 82(4B):40J-46J. PubMed ID: 9737645
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluvastatin on human biliary lipids.
Tazuma S; Ohya T; Mizuno T; Takizawa I; Kunita T; Takata K; Hayashi K; Hino F; Tokumo H; Watanabe T
Am J Cardiol; 1995 Jul; 76(2):110A-113A. PubMed ID: 7604783
[TBL] [Abstract][Full Text] [Related]
9. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductase inhibitor, in patients with primary hypercholesterolemia.
Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S
Clin Ther; 1998; 20(3):539-48. PubMed ID: 9663369
[TBL] [Abstract][Full Text] [Related]
10. [A comparative long-term trial of sodium cerivastatin, a new HMG-CoA reductase inhibitor, in patients presenting with primary hypercholesterolemia].
Sasaki J; Arakawa K; Yamamoto K; Kobori S; Ageta M; Kono S
Rev Med Interne; 1999 Aug; 20 Suppl 3():393s-398s. PubMed ID: 10480191
[TBL] [Abstract][Full Text] [Related]
11. Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.
Tazuma S; Takizawa I; Kunita T; Mizuno T; Watanabe T; Teramen K; Horikawa K; Ochi H; Yamashita Y; Aihara N
Metabolism; 1995 Nov; 44(11):1410-2. PubMed ID: 7476326
[TBL] [Abstract][Full Text] [Related]
12. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia.
Plosker GL; Dunn CI; Figgitt DP
Drugs; 2000 Nov; 60(5):1179-206. PubMed ID: 11129127
[TBL] [Abstract][Full Text] [Related]
13. Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.
Tazuma S; Yamashita G; Ochi H; Miura H; Kajihara T; Hattori Y; Miyake H; Nishioka T; Hyogo H; Sunami Y; Yasumiba S; Kajiyama G
Clin Ther; 1998; 20(3):477-85. PubMed ID: 9663363
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
